Are vancomycin trough concentrations adequate for optimal dosing?

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 309-316

  Neely, Michael N ^a,b   Youn, Gilmer ^a   Jones, Brenda ^a   Jelliffe, Roger W ^a,b   Drusano, George L ^c   Rodvold, Keith A ^d   Lodise, Thomas P ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG CONCENTRATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 84891518844     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01653-13     Document Type: Article

References (38)

1. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
2. Suzuki Y, Kawasaki K, Sato Y, Tokimatsu I, Itoh H, Hiramatsu K, Takeyama M, Kadota J-I. 2012. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokineticpharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy 58:308-312. http://dx.doi.org/10.1159/000343162.
3. Tobin CM. 2002. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of aUKNational External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J. Antimicrob. Chemother. 50:713-718. http://dx.doi.org/10.1093/jac/dkf212.
4. Fitzsimmons WE, Postelnick MJ, Tortorice PV. 1988. Survey of vancomycin monitoring guidelines in Illinois hospitals. Drug Intell. Clin. Pharm. 22:598-600.
5. Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA. 2013. A stewardship rogram's retrospective evaluation of vancomycin AUC24/ MIC and time to microbiological clearance in patients with methicillinresistant Staphylococcus aureus bacteremia and osteomyelitis. Clin. Ther. 35:772-779. http://dx.doi.org/10.1016/j.clinthera.2013.05.008.
6. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MVN, Anderson TL, Roberts SA, Warren SJC, Gao W, Howden BP, Johnson PDR. 2013. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 57:1654-1663. http://dx.doi.org/10.1128/AAC.01485-12.
7. Brown J, Brown K, Forrest A. 2012. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob. Agents Chemother. 56:634-638. http://dx.doi.org/10.1128/AAC.05609-11.
8. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942. http://dx.doi.org/10.2165/00003088-200443130-00005.
9. Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC. 1990. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob. Agents Chemother. 34:1165- 1171. http://dx.doi.org/10. 1128/AAC.34.6.1165.
10. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, Riff LJ. 1988. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob. Agents Chemother. 32:848-852. http://dx.doi.org/10. 1128/AAC.32.6.848.
11. Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. 2011. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob. Agents Chemother. 55:5507-5511. http://dx.doi.org/10. 1128/AAC.00712-11.
12. Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA, Kett DH, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group. 2012. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin. Ther. 34:149-157. http://dx.doi.org/10.1016/j.clinthera.2011.12. 013.
13. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514. http://dx.doi.org/10.1086/600884.
14. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. 2012. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 32:195-201. http://dx.doi.org/10.1002/j. 1875-9114.2011.01017.x.
15. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. 2010. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am. J. Med. 123:1143-1149. http://dx.doi.org/10.1016/j.amjmed. 2010.07.025.
16. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. 2012. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J. Antimicrob. Chemother. 67:17-24. http://dx.doi.org/10.1093/jac/dkr442.
17. Jelliffe R. 2002. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am. J. Nephrol. 22:320-324. http://dx.doi.org/10.1159/000065221.
18. Charhon N, Neely MN, Bourguignon L, Maire P, Jelliffe RW, Goutelle S. 2012. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. Antimicrob. Agents Chemother. 56:1862-1869. http://dx.doi.org/10.1128/AAC.05634-11.
19. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit. 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
20. R Core Team. 2013. R: A language and environment for statistical computing. R project, 3rd ed. R Foundation for Statistical Computing, Vienna, Austria.
21. Leary RH, Jelliffe R, Schumitzky A, Van Guilder M. 2001. An adaptive grid non-parametric approach to population pharmacokinetic/dynamic (PK/PD) population models, p 389-394. Proceedings 14th IEEE Symposium on Computer-Based Medical Systems, Bethesda, MD.
22. Tatarinova T, Neely M, Bartroff J, Van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A. 2013. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J. Pharmacokinet. Pharmacodyn.40:189-199. http://dx.doi.org/10.1007/s10928-013-9302-8.
23. Marsot A, Boulamery A, Bruguerolle B, Simon N. 2012. Vancomycin: A review of population pharmacokinetic analyses. Clin. Pharmacokinet. 51: 1-13. http://dx.doi.org/10.2165/11596390-000000000-00000.
24. Neely M, Jelliffe R. 2008. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J. Clin. Pharmacol. 48:1081-1091. http://dx.doi.org/10.1177/0091270008321789.
25. Jelliffe R, Bayard D, Milman M, Van Guilder M, Schumitzky A. 2000. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. Ther. Drug Monit. 22:346-353. http://dx.doi.org/10.1097/00007691-200006000-00018.
26. Jelliffe RW, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, Barbaut X, Maire P. 1998. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new "multiple model" dosage design, Bayesian feedback and individualised target goals. Clin. Pharmacokinet. 34:57-77.
27. Bayard DS, Jelliffe RW. 2004. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J. Pharmacokinet. Pharmacodyn. 31:75-107. http://dx.doi.org/10.1023/B:JOPA.0000029490.76908.0c.
28. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981. http://dx.doi.org/10.1093/cid/cir124.
29. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. 2012. Linezolid in methicillin- resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin. Infect. Dis. 54:621-629. http://dx.doi.org/10.1093/cid/cir895.
30. Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, Capparelli EV. 2013. Improved vancomycin dosing in children using area under the curve exposure. Pediatr. Infect. Dis. J. 32:e155- 63. http://dx.doi.org/10.1097/INF.0b013e318286378e.
31. Frymoyer A, Guglielmo BJ, Hersh AL. 2013. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr. Infect. Dis. J. 32:1077-1079. http://dx.doi.org/10.1097/ INF.0b013e318299f75c.
32. Minne L, Eslami S, Kuiper RA, Abu-Hanna A, Dongelmans DA. 2012. Five years of therapeutic drug monitoring in the intensive care did not change vancomycin prescription behaviour: perceived needs for decision support. Minerva Anestesiol. 78:684-692. http://www.minervamedica.it/en/getfreepdf/ bWdpwBzTIRpiYEwNhZn%252BCzz9ea01G5Ir7aFX5c%252BUgtD6OqGodgGufhX69qPyD1SAvRPkbu8 lLjnyc6iRStyl9A%253D%253D/R02Y2012N06A0684.pdf.
33. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. 2011. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann. Pharmacother. 45:757-763. http://dx.doi.org/10.1345/aph.1P634.
34. Rodvold KA, Rotschafer JC, Gilliland SS, Guay DR, Vance-Bryan K. 1994. Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies. Ther. Drug Monit. 16:37-41. http://dx.doi.org/10.1097/ 00007691-199402000-00005.
35. D'Argenio DZ. 1981. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Pharmacodyn. 9:739-756. http://dx.doi.org/10. 1007/BF01070904.
36. Burstein AH, Gal P, Forrest A. 1997. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Ann. Pharmacother. 31: 980-983.
37. Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ, Holmes NE, Howden BP, Paterson DL. 2013. Vancomycin therapeutics and monitoring: A contemporary approach. Intern. Med. J. 43:110-119. http://dx.doi.org/10.1111/imj.12036.
38. Neely M, Jelliffe R. 2010. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J. Clin. Pharmacol. 50: 842-847. http://dx.doi.org/10.1177/0091270009356572.